Metrics other than potency reveal systematic variation in responses to cancer drugs - Dataset (ID:20120)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
| HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
|---|---|---|---|---|---|
| 10013-3 | GSK461364 | GSK461364A | LSM-1013 |  | 15983966 |
| 10021-5 | Tozasertib | VX680; MK-0457 | LSM-1021 |  | 5494449 |
| 10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 |  | 5291 |
| 10026-3 | PD173074 | LSM-1026 |  | 1401 | |
| 10035-2 | Sigma A6730 | KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor | LSM-1035 |  | 10196499 |
| 10062-3 | GSK1070916 | KIN001-216 | LSM-1062 |  | 46885626 |
| 10097-3 | Erlotinib | OSI-774 | LSM-1097 |  | 176870 |
| 10098-2 | Gefitinib | ZD1839; Iressa | LSM-1098 |  | 123631 |
| 10102-3 | Taxol | Paclitaxel | LSM-1102 |  | 441276 |
| 10107-2 | MG-132 | LSM-1107 |  | 462382 | |
| 10142-2 | Trametinib | GSK-1120212; GSK1120212; GSK1120212B; JTP-74057 | LSM-1143 |  | 11707110 |
| 10146-2 | Omipalisib | GSK2126458; GSK2126458A | LSM-1147 |  | 25167777 |
| 10172-2 | GSK1059615 | LSM-1173 |  | 71317162 | |
| 10189-2 | Bosutinib | SKI-606 | LSM-1190 |  | 5328940 |
| 10223-2 | AG1478 | Tyrphostin | LSM-1224 |  | 2051 |
| 10230-2 | Lestaurtinib | CEP-701 | LSM-1231 |  | 126565 |
| 10266-1 | NSC 663284 | LSM-2042 |  | 379077 | |
| 10249-1 | Epirubicin | Ellence | LSM-2078 |  | 41867 |
| 10246-1 | CPT-11 | Irinotecan | LSM-2167 |  | 60838 |
| 10228-2 | IKK16 | LSM-2309 |  | 9549298 | |
| 10280-1 | Triciribine | LSM-3810 |  | 65399 | |
| 10282-1 | Vorinostat | suberoylanilide hydroxamic acid (SAHA); Zolinza | LSM-3828 |  | 5311 |
| 10248-1 | Doxorubicin | Adriamycin | LSM-4062 |  | 31703 |
| 10235-2 | Everolimus | RAD001 | LSM-4258 |  | 53398658 |
| 10238-1 | 5-FU | Fluorouracil | LSM-4261 |  | 3385 |